Deferred Income Tax Expense (Benefit) in USD of Estrella Immunopharma, Inc. from 2022 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Estrella Immunopharma, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and change rate from 2022 to Q1 2023.
  • Estrella Immunopharma, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending 31 Mar 2023 was -$21.7K.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), Annual (USD)

Estrella Immunopharma, Inc. Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 -$21.7K 01 Jan 2023 31 Mar 2023 10-Q 18 May 2023

Estrella Immunopharma, Inc. Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $29.5K 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.